Group 1 - Prostate cancer is the second most common tumor type among men globally, with approximately 1 in 9 men diagnosed in their lifetime [1][2] - President Biden has been diagnosed with malignant prostate cancer, with cancer cells having spread to his bones, and his Gleason score is reported to be 9, indicating a highly aggressive form of the disease [1][2] - The treatment options for prostate cancer are diverse and should be personalized based on individual patient circumstances, potentially involving a combination of therapies such as hormone therapy, chemotherapy, or radiation [3] Group 2 - Recent advancements in the development of new prostate cancer drugs have been made, with the FDA approving enzalutamide (brand name: Xtandi) for a new indication in November 2023, marking it as the first approved treatment for high-risk non-metastatic castration-sensitive prostate cancer [3] - The five-year survival rate for metastatic prostate cancer in China is reported to be less than 50%, with 20%-30% of patients already having metastasis at the time of initial diagnosis [2] - Prostate cancer typically has a slower progression compared to other malignancies, allowing patients to maintain a relatively normal life and quality of life even in high-risk cases [3]